NDA 18471, held by Bayer Healthcare LLC. Oxymetazoline Hydrochloride.
As of Nov 13, 2026, NDA 18471 (Ocuclear), held by Bayer Healthcare LLC, was first approved by FDA on May 30, 1986, with 14 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 30, 1986 | Original applicationNew dosage form · Standard review | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ocuclear0.025% · solution/drops;ophthalmic | Oxymetazoline Hydrochloride | Discontinued |
| Jun 6, 2001 | Supplement 16Manufacturing · Standard review | Approved | None posted |
| Jan 24, 2001 | Supplement 15Manufacturing · Standard review | Approved | None posted |
| Jul 14, 1997 | Supplement 14Manufacturing · Standard review | Approved | None posted |
| Nov 13, 1996 | Supplement 13Manufacturing · Standard review | Approved | None posted |
| May 16, 1990 | Supplement 12Manufacturing · Standard review | Approved | None posted |
| Aug 24, 1989 | Supplement 11Labeling | Approved | None posted |
| Jun 9, 1989 | Supplement 7Manufacturing · Standard review | Approved | None posted |
| Apr 6, 1989 | Supplement 8Manufacturing · Standard review | Approved | None posted |
| Mar 30, 1989 | Supplement 6Manufacturing · Standard review | Approved | None posted |
| Jan 15, 1988 | Supplement 5Manufacturing · Standard review | Approved | None posted |
| Aug 4, 1987 | Supplement 4Manufacturing · Standard review | Approved | None posted |
| Aug 3, 1987 | Supplement 2Manufacturing · Standard review | Approved | None posted |
| May 12, 1987 | Supplement 3Manufacturing · Standard review | Approved | None posted |
| Aug 20, 1986 | Supplement 1Manufacturing · Standard review | Approved | None posted |
| May 30, 1986 | Original applicationNew dosage form · Standard review | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters